Trial · NCT01369355
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Week 0 - Week 44 (Maintenance) | STARTED | Ustekinumab Induction Responders(UST-I-Rsp)Placebo Maintenance | 133 | |
| Week 0 - Week 44 (Maintenance) | STARTED | UST-I-Rsp-UST-90 mg Every 12 Weeks (Q12W) Maintenance | 132 | |
| Week 0 - Week 44 (Maintenance) | STARTED | UST-I-Rsp-UST-90 mg Q8W Maintenance | 132 | |
| Week 0 - Week 44 (Maintenance) | STARTED | Placebo (PBO)-I-Rsp - PBO Maintenance | 123 | |
| Week 0 - Week 44 (Maintenance) | STARTED | PBO-I-nonRsp - UST-130mg Intravenous/90mg SC Q12W Maintenance | 285 | |
| Week 0 - Week 44 (Maintenance) | STARTED | UST-I-nonRsp - UST-90mg Subcutaneously (SC) Q8W Maintenance | 476 | |
| Week 0 - Week 44 (Maintenance) | STARTED | Placebo Long Term Extension (LTE) | 0 | |
| Week 0 - Week 44 (Maintenance) | STARTED | UST 90 mg SC Q12W LTE | 0 | |
| Week 0 - Week 44 (Maintenance) | STARTED | UST 90 mg SC Q8W LTE | 0 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | Ustekinumab Induction Responders(UST-I-Rsp)Placebo Maintenance | 102 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | UST-I-Rsp-UST-90 mg Every 12 Weeks (Q12W) Maintenance | 103 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | UST-I-Rsp-UST-90 mg Q8W Maintenance | 101 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | Placebo (PBO)-I-Rsp - PBO Maintenance | 93 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | PBO-I-nonRsp - UST-130mg Intravenous/90mg SC Q12W Maintenance | 131 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | UST-I-nonRsp - UST-90mg Subcutaneously (SC) Q8W Maintenance | 204 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | Placebo Long Term Extension (LTE) | 0 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | UST 90 mg SC Q12W LTE | 0 | |
| Week 0 - Week 44 (Maintenance) | COMPLETED | UST 90 mg SC Q8W LTE | 0 | |
| Week 0 - Week 44 (Maintenance) | NOT COMPLETED | Ustekinumab Induction Responders(UST-I-Rsp)Placebo Maintenance | 31 | |
| Week 0 - Week 44 (Maintenance) | NOT COMPLETED | UST-I-Rsp-UST-90 mg Every 12 Weeks (Q12W) Maintenance | 29 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01369355/flow